Pfizer and Moderna have been unanimously endorsed by the CDC’s Independent Panel of Vaccine Scientists. It is the last regulatory step before the U.S. may begin distributing doses.

The shots were approved by the Advisory Committee on Immunization Practices. Both vaccine boosters were approved by the Food and Drug Administration earlier Friday. CDC Director Rochelle Wilensky will likely clear the dosages shortly after.

Although eligibility is now open to all Americans 18 years and older in the U.S.A, the panel strongly supported shots for seniors Americans and recommended that everyone over 50 be eligible. ShouldGet a booster. The original recommendation stated that anyone over 65 years old and other people at higher risk need a booster.

After Walensky has signed off, the tens and millions of Americans who received their first shots at least six month ago are eligible for a second shot.

According to Dr. John Perez (Vice President of Pfizer’s vaccine clinical researcher program), the booster was 95% effective in stopping symptomatic infections in patients who did not have evidence of previous infection. The clinical trial involved 10,000 people aged 16 and over. Moderna told the panel that it is still collecting data on its booster’s efficacy.

The panel was informed by Dr. Sara Oliver from the CDC that while more than 195,000,000 Americans have been fully vaccinated, there are still many cases of covid in areas where the effectiveness of vaccines is decreasing over time.

Oliver stated that “Overall protection for severe diseases remains high and hospitalizations and waning effectiveness appears to be less for Moderna than for Pfizer.” But, there’s evidence that Moderna shots are associated with a greater risk of myocarditis, a rare condition that affects the heart, than Pfizer.

Director of Maine’s CDC and President of the Association of State and Territorial Health Officials Dr. Nirav Shaikh said that the existing guidelines can be confusing and create more work for the state and local officials responsible for determining who is eligible. According to the group, the CDC should distribute the shot to anyone 18 or older.

He explained to the panel that the move would help ease the pressure on staff at the state immunization programs, which are currently dealing with a large volume of eligibility questions.

According to data, side effects of Moderna and Pfizer’s third shots had been reported as mild by the vast majority of participants. These included pain at the injection site and headaches.

Moderna discovered that the booster doses had side effects similar to the ones experienced by patients following the first two-dose series. These included headaches, fatigue, muscle pains and muscle aches.

According to Rituparna Das who represented Moderna at the meeting, however, safety data is being collected by the company as the clinical trial of over 15,000 participants continues.

In a Friday presentation, the Centers for Disease Control and Prevention found 54 cases of myocarditis and pericarditis in nearly 26 million Pfizer and Moderna booster shots. This is approximately 2.1 cases for every 1 million administered. Only 12 cases of myocarditis and myopericarditis were reported so far. 38 others are currently under review, while four have been ruled out.

Myocarditis, which is an inflammation of the heart muscle and pericarditis, is inflammation in the outer lining. They are known as myopericarditis when the conditions combine.

According to the CDC, people also reported fewer side effect from Moderna boosters and Pfizer than they did from their primary two-dose regimen.

Original advisory panel of the CDC declined in September to endorse Pfizer’s boostersThe public should support an alternative distribution program for older Americans and individuals who have underlying conditions that increase their risk of Covid infection.

Experts on the panel stated that the safety data available, which was based upon research from 306 people who had received boosters, was not sufficient to determine the risk posed by myocarditis and other rare side effects.

The panel endorsed Moderna’s boosters for elderly Americans and people with underlying health conditions in October as well as Johnson & Johnson boosters for everyone age 18 and over.

Public health debates the issue of broad-based administration of booster doses. The World Health Organization repeatedly condemned wealthy countries for offering third shots while people living in poverty have only limited access.

The debate over booster doses has also been heated in the U.S. Experts are questioning whether it is time for third shots to be introduced when 60 million Americans have not received their first shot.

To their credit, however, the state officials from California and Maine had already started rolling out boosters for all adultsBefore the CDC recommendation of Friday.

As evidence is mounting that the effectiveness of vaccines against infections decreases over time, many Americans are seeking an additional layer of protection. As Americans gather indoors in the cold to avoid the winter, public health professionals expect an increase of infection.

People who have been vaccinated may be able to receive booster doses, which could reduce the risk of transmission and prevent breakout infections.